Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Damaris B. Skouras

Piscitelli Philip

Jeanette Rooney, CPA, CGMA

Cynthia (Dana) Barrow

Mustafa Noor

Joseph St. Laurent

Charles A. Dinarello

Scientific Advisors

Leadership Team

Clinical Advisors

Clinical Development

��

Teams at Olatec Therapeutics

Scientific Advisors

Leadership Team

Clinical Advisors

Clinical Development

��������

Teams at Olatec Therapeutics

Scientific Advisors

Leadership Team

Clinical Advisors

Clinical Development

��